Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

Antimicrobial Agents and Chemotherapy
L de RepentignyK De Beule

Abstract

The safety, tolerability, and pharmacokinetics of an oral solution of itraconazole and its active metabolite hydroxyitraconazole were investigated in an open multicenter study of 26 infants and children aged 6 months to 12 years with documented mucosal fungal infections or at risk for the development of invasive fungal disease. The most frequent underlying illness was acute lymphoblastic leukemia, except in the patients aged 6 months to 2 years, of whom six were liver transplant recipients. The patients were treated with itraconazole at a dosage of 5 mg/kg of body weight once daily for 2 weeks. Blood samples were taken after the first dose, during treatment, and up to 8 days after the last itraconazole dose. On day 1, the mean peak concentrations in plasma after the first and last doses (Cmax) and areas under the concentration-time curve from 0 to 24 h (AUC0-24) for itraconazole and hydroxyitraconazole were lower in the children aged 6 months to 2 years than in children aged 2 to 12 years but were comparable on day 14. The mean AUC0-24-based accumulation factors of itraconazole and hydroxyitraconazole from day 1 to 14 ranged from 3.3 to 8.6 and 2.3 to 11.4, respectively. After 14 days of treatment, Cmax, AUC0-24, and the half-l...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F PersatM A Piens
Mar 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L de Repentigny
Jun 1, 1992·The Journal of Pediatrics·J W LeeT J Walsh
Dec 1, 1991·The Journal of Pediatrics·P A PizzoT J Walsh
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·T C HardinJ G Kuhn
Jan 1, 1987·Reviews of Infectious Diseases·H Van CauterenG Cauwenbergh
Oct 1, 1984·Antimicrobial Agents and Chemotherapy·J Van CutsemP A Janssen
Aug 1, 1994·The Journal of Antimicrobial Chemotherapy·A G PrenticeD A Oliver
Aug 1, 1994·The American Journal of Medicine·D W DenningA Catanzaro

❮ Previous
Next ❯

Citations

Apr 17, 2001·Antimicrobial Agents and Chemotherapy·C SchmittJ C Levron
Apr 17, 2001·Pediatric Annals·A Spray, E Siegfried
Apr 17, 2001·The Pediatric Infectious Disease Journal·C A Rodriguez, C C Patrick
Jun 26, 2001·Journal of Clinical Pharmacy and Therapeutics·L WillemsK de Beule
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·B M Boyle, S R McCann
Oct 12, 2007·Paediatric Drugs·Benito Almirante, Dolors Rodríguez
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Christine C ChiouAndreas H Groll
Jan 26, 2008·British Journal of Haematology·Reinhard A Seger
Mar 14, 2008·Toxicologic Pathology·Valentino J Stella, Quanren He
Mar 30, 2021·International Journal of Pharmaceutics·Helen Haixia WuBlech Michaela
Apr 26, 2016·Expert Opinion on Drug Metabolism & Toxicology·Jennifer L Goldman, Susan M Abdel-Rahman
Nov 4, 2016·World Journal of Pediatrics : WJP·Shuang ChenYu-Ping Ran
Nov 15, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Athanasios TragiannidisAndreas H Groll
Oct 31, 2002·Clinical Pharmacokinetics·Jane Alcorn, Patrick J McNamara
Jul 27, 2017·Clinical and Experimental Pharmacology & Physiology·Sarah AllegraAntonio D'Avolio
Feb 14, 2019·Journal of Fungi·Savvas PapachristouEmmanuel Roilides
Nov 7, 2012·British Journal of Clinical Pharmacology·Jodi M LestnerWilliam W Hope
May 19, 2021·Clinical Pharmacokinetics·Didi BuryRoger J Brüggemann
May 7, 2013·Expert Opinion on Drug Metabolism & Toxicology·Jodi Lestner, William W Hope
Sep 26, 2019·Expert Opinion on Drug Metabolism & Toxicology·Jamie JohnThomas J Walsh
Sep 11, 2009·Current Opinion in Infectious Diseases·Michael Cohen-WolkowiezPhillip B Smith
May 21, 2005·Therapeutic Drug Monitoring·Susan S BuchkowskyMary H H Ensom
Jan 1, 2014·The Journal of Antimicrobial Chemotherapy·H Ruth AshbeeWilliam W Hope
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter G PappasUNKNOWN Infectious Diseases Society of America
Mar 7, 2014·Clinical Pharmacokinetics·Chris StockmannCatherine M T Sherwin
Jun 13, 2016·Journal of Fungi·Rachel L Wattier, Lynn Ramirez-Avila
Jan 13, 2015·Expert Opinion on Pharmacotherapy·Theodouli Stergiopoulou, Thomas J Walsh
Mar 31, 2018·The Pediatric Infectious Disease Journal·Ying Hua LeongAmanda Gwee
Jan 25, 2020·Paediatric Drugs·Kevin J DownesNicole R Zane
Nov 9, 2004·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Rakesh K MondalJayashree M
Sep 1, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Arne SimonGudrun Fleischhack
Jan 11, 2007·Antimicrobial Agents and Chemotherapy·Gopal KrishnaLisa Pedicone
May 23, 2007·Antimicrobial Agents and Chemotherapy·Susan M Abdel-RahmanJeffrey L Blumer
Feb 9, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M Echezarreta-LópezJ L Vila-Jato
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Feb 24, 2001·Drugs·K De Beule, J Van Gestel
Jun 21, 2001·The Annals of Pharmacotherapy·D SlainS W Chapman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.